Vermillion Announces Notice of Issuance of U.S. Patent Covering Hepcidin as a Biomarker for Ovarian Cancer
News Feb 17, 2009
Vermillion, Inc. has announced that the U.S. Patent Office (USPTO) has issued a notice of allowance to the Company for the discovery of hepcidin as a biomarker for ovarian cancer. The discovery could ultimately lead to the development of an improved, next-generation assay that might provide physicians with additional, valuable information to diagnose ovarian cancer.
"The notice of issuance of this patent validates the strength of our approach in the development of innovative molecular diagnostics," said Eric T. Fung, M.D., Ph.D, Chief Scientific Officer of Vermillion and co-inventor. "This patent comprises an important component of our ovarian cancer patent portfolio."
The patent also covers the measurement of hepcidin by a variety of methods, including mass spectrometry and other immunoassay approaches.
Retrained Enzyme is Biocatalysis MilestoneNews
TU Graz researchers managed for the first time ever to ‘retrain’ an enzyme to build ring-shaped molecular structures instead of performing its natural task of reducing double bonds. The work was published in Angewandte Chemie, and is relevant for the production of pharmaceuticals and plant protection products.
Laser Pulses and Fluorescence Enable Metabolite ViewingNews
In the search for new sources of drugs, biodegradables and biofuels scientists have come to realize that life itself could be the solution, using natural metabolites produced by bacteria to produce vital compounds like penicillin. Identifying which cells are most useful for this goal has proved a huge challenge, but a new system using fluorescence and lasers has enabled metabolite viewing in real time in algae cells.READ MORE
Comments | 0 ADD COMMENT
12th International Conference on Advancements in Bioinformatics and Drug Discovery
Nov 26 - Nov 27, 2018